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We read with great interest a recent article in the Journal of Hepa-
tology by Ishikawa et al. investigating the role of CD1d-restricted
natural killer T (NKT) cells in thioacetamide (TAA)-induced liver
ﬁbrosis, by using CD1d knockout (KO) mice that are associated
with NKT cell deﬁciency [1]. First, the authors observed that
CD1d KO mice were resistant to TAA-induced liver inﬂammation,
damage, and hepatocyte apoptosis. Second, the authors observed
CD1d KO mice were resistant to TAA-induced liver ﬁbrosis, indi-
cating that NKT cells play an important role in promoting liver
ﬁbrogenesis in mice after chronic TAA treatment. The pro-ﬁbrotic
effects of NKT cells were also recently suggested by the data from
a murine model of HBV transgenic mice [2], primary biliary cir-
rhosis [3], nonalcoholic steatohepatitis (NASH), and patients with
NASH [4].
Recently, we identiﬁed the double sword face of invariant
NKT (iNKT, type I NKT) cells in liver ﬁbrogenesis in a model
of CCl4-induced liver injury [5]. On the one hand, iNKT-deﬁ-
cient mice had increased liver injury and ﬁbrosis, especially
in the early stage of CCl4-induced liver injury, suggesting that
natural activation of iNKT cells by endogenous lipid antigens
plays a protective role in preventing CCl4-induced liver injury
and ﬁbrosis. On the other hand, strong activation of iNKT cells
by a-galactosylceramide (a-GalCer) accelerated CCl4-induced
hepatocellular injury and subsequently enhanced ﬁbrosis. Our
ﬁndings clearly suggest a complex role of iNKT cells in liver
ﬁbrosis: inhibiting liver ﬁbrosis via the suppression of HSC
activation or indirectly promoting liver ﬁbrosis via enhancing
liver injury. We believe that the ﬁnal effect of iNKT cells on
liver ﬁbrosis is determined by the balance between the inhib-
itory and stimulatory effects as we discussed above, but may
also dependent on the real context of developing stage human
liver diseases or animal models used. In addition to iNKT (type
I NKT) cells, other subtypes of NKT cells including type II and
possible type III NKT cells also exist [6]. These different sub-
types of NKT cells exert many similar functions but may also
exert some opposing functions, which further complicates the
role of NKT cells in liver ﬁbrogenesis [6,7].
In the study by Ishikawa et al. [1], it appears that CD1d
restricted NKT cells play an important role in inducing liver
injury, which may contribute to the pro-ﬁbrotic effects of NKTJournal of Hepatology 201cells observed in the TAA-induced liver injury model. In the Sup-
plementary material, Ishikawa et al. [1], reported that CD1d KO
mice were also resistant to CCl4-induced acute liver injury; how-
ever, we found that CD1d KO mice had similar liver injury and
ﬁbrosis after chronic treatment with CCl4 (Park et al., unpublished
data). Further studies are required to clarify the complex role of
NKT cells in liver injury and ﬁbrosis.
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Clin Immunol 2009;130:16–26.Reply to: ‘‘NKT cells in liver ﬁbrosis: Controversies or complexities’’To the Editor:
Emerging attention has been paid to the role of natural killer T
(NKT) cells in a variety of liver diseases including nonalcoholicsteatohepatitis (NASH) [1]. The role of NKT cells in hepatic ﬁbro-
genesis, however, has been controversial [2–4]. In our latest man-
uscript entitled ‘‘CD1d-restricted natural killer T cells contribute1 vol. 55 j 1162–1168
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to hepatic inﬂammation and ﬁbrogenesis in mice’’, we demon-
strated that CD1d-restricted natural killer (NK) T cells play an
exacerbating role in xenobiotics-induced liver injury and subse-
quent ﬁbrogenesis using CD1d-knockout (KO) mice [5]. As Dr.
HuaWang et al. pointed out in their letter, however, the functions
of NKT cells in liver pathophysiology appear to be more complex
in nature.
It is an intriguing hypothesis that NKT cells act as a double-
sword in liver pathophysiology. It is indeed quite reasonable, con-
sidering the fact that NKT cells produce a variety of mediators
including both Th1 and Th2 cytokines. From these important char-
acteristics, NKT cells are often called as ‘‘the regulator of Th1/Th2
balance’’; however, the precise mechanisms by which NKT cells
modulate the balance in quantity and timing to produce these
cytokines following speciﬁc stimuli have not beenwell elucidated.
Park et al. demonstrated the complicated roles of NKT cells in
acute and chronic liver injury caused by CCl4 [4]. Although their
hypothesis is fascinating, the experimental design of their study
needs attention. In their study, a-galactosylceramide (GalCer), a
speciﬁc ligand to invariant T cell receptor (TCR) in NKT cells,
was used to stimulate these cells. Indeed, it is well established
that GalCer causes a variety of responses in NKT cells, from the
early activation phasewith cytokine production to the subsequent
tolerant state. Typically, a single injection of GalCer induces inac-
tivation and/or apoptotic death of NKT cells systemically, the
effect lasting a few days. Moreover, GalCer itself induces consider-
able degree of liver injury in mice [6]. Therefore, the timing/inter-
val of pretreatment is obviously critical for the alterations in the
innate immune microenvironment in the liver caused by GalCer.
The discrepancies between our observations and theirs can be
explained in part by the fact that NKT cells consist of heteroge-
neous subsets of lymphocytes which express both NK and T cell
surface markers. Classical, type I NKT cells express invariant T cell
receptor (TCR), which is a complex of Va14-Ja18 chain and b2
macroglobulin heterodimer. In contrast, non-classical, type II
NKT cells contain a different type of TCR, which also recognizes
glycolipid antigens in a CD1d-restricted manner [7]. CD1d-KO,
therefore, lack both type I and type II NKT cells, whereas Va14-
Ja18-KO mice are defective in type I NKT cells alone and maintain
type II NKT cells intact. Therefore, it is quite important to note
which type of KO mice are used in the study. The functional dif-
ferences between type I and type II NKT cells in liver pathophys-
iology still remain unclear. Recently, we investigated the
differences in acute thioacetamide (TAA) intoxication between
CD1d-KO and Va14-KO mice (unpublished observations). As
described in our manuscript, CD1d-KO mice are protected against
TAA-induced mortality; however, the mortality rates following a
single injection of TAA in Va14-KO mice were almost similar as in
wild-type (WT) animals. The necro-inﬂammatory responses, as
well as the elevation in serum aminotransferases levels, were sig-Journal of Hepatology 2011niﬁcantly improved in Va14-KO mice in comparison with WT
mice, but the degree of liver injury was much severer as com-
pared to CD1d-KO mice. The difference in TAA-intoxication
between CD1d- and Va14-KO mice suggests the differential role
in type I and type II NKT cells. These ﬁndings indicate that type
I NKT cells seem to play a major role in systemic inﬂammatory
responses, which lead to mortality in bothWT and Va14-KO mice.
On the other hand, type II NKT cells alone can promote TAA-
induced liver injury in part, even in the absence of type I NKT
cells. It is intriguing to investigate the differences in induction
of cytokines in each subset, especially from the aspect of the
Th1/Th2 balance. Collectively, it is suggested that type I and type
II NKT cells synergistically participate in the development of
acute TAA-induced liver injury.
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